Heparin Calcium

导语：12月16日，爱施健中国与重药集团举行战略合作签约仪式。此次签约标志着双方将以战略合作伙伴身份，全方位、多角度开展深入合作。 会场全景 12月16日，爱施健中国与重药集团举行战略合作签约仪式，双方将进一步整合优势资源，聚力推动速碧林®低分子肝素钙注射液在全国广阔市场的覆盖，并以此为锚点，探索更全面、更深入的合作，以全球视野和国企担当，为实现“健康中国2030”献策献力，使药品惠及广大患者。 爱施健中国区首席执行官Larry Merizalde先生，爱施健政府事务及市场准入部副总经理杨晓燕女士，爱施健商务总监李刚先生，重药集团董事长袁泉先生，重药集团总裁刘伟先生，重药集团常务副总裁李少宏先生，重药集团副总裁朱萸先生等出席活动。 当前，随着中国人口老龄化进程的加速，公共卫生体系面临巨大挑战。其中，静脉血栓栓塞症（VTE）作为一种常见且严重的并发症，其发病率显著上升，成为威胁老年人健康的一大隐患。针对这一现状，低分子肝素钙注射液在提升VTE防治水平方面发挥了重要作用，有效促进了中国VTE规范预防率的提升，为患者健康提供坚实保障。 爱施健中国区首席执行官Larry Merizalde 爱施健中国区首席执行官Larry Merizalde先生表示，非常荣幸能够与重药集团举行战略签约。麻醉、抗血栓、消化和骨质疏松是爱施健中国的核心治疗领域，而速碧林®是我们抗血栓治疗领域中最重要的领先品牌之一。多年来，爱施健中国与重药集团始终保持着良好且成功的合作关系。此次合作是新爱施健中国在可持续、有机增长之路上迈出的第一个重要里程碑，也是新征程的良好开端。未来，我们将充分整合彼此的优势资源，造福中国患者。 重药集团总裁刘伟 重药集团总裁刘伟先生表示，此次合作正是双方在长期合作的基础上的全面升级。重药集团将依托全国布局，尝试模式创新，从战略层面助力合作成功。 签约仪式 会上，双方进行了深入沟通交流，共同分析了前期合作进展、资源整合情况，探讨了如何在今后合作中进一步精准对接彼此需求，实现优势互补，互利共赢。李少宏先生与杨晓燕女士代表双方企业共同签署了战略协议。 重药集团董事长袁泉 袁泉董事长做会议总结，他表示重药集团将从协助挂网，准入推广，数字化转型，通用下属医疗板块合作等方面给予爱施健中国全供应链的现代医药服务。重药集团即将迎来历史发展新阶段，双方在恰当的时机遇到志同道合的伙伴，定能助力业绩持续增长，服务更多中国患者！ 关于爱施健集团 爱施健集团作为一家跨国制药公司，总部位于南非德班，始于1850年，拥有170年的悠久历史，业务覆盖各类新兴市场和成熟市场。爱施健集团在全球设立63个办公室，拥有9,300多名员工，在6大洲设立24家生产工厂，向超过115个国家和地区提供优质和患者可及的药物致力于提高患者生命健康。爱施健集团连续举办年度“纳尔逊·曼德拉国际日（曼德拉日）”公益项目14余年，在40多个国家和地区累计开展了880多项社会经济发展公益项目。 爱施健集团创始人兼集团首席执行官Stephen Saad先生于2016年荣获全非洲年度企业家奖，2021年法国马克龙总统授予Stephen Saad先生法国国家功绩骑士勋章。2020年7月爱施健集团首次被纳入富时罗素社会责任投资指数成分股(FTSE4Good Index Series)。2022年2月12日爱施健集团荣获由南非政府和南非国际关系与合作部 (DIRCO)颁发的经济外交（全球）类乌班图奖。2022年3月25日爱施健集团荣获由南非总统西里尔·拉马福萨（Cyril Ramaphosa）颁发的荣誉奖项SAIC卓越企业奖。 关于爱施健中国 2015年，爱施健集团在中国成立第一家公司。继收购葛兰素史克(GSK)抗血栓药物和阿斯利康（AZ）麻醉药组合，2017年爱施健集团以充分实力全面进军中国市场。2024年爱施健集团完成收购山德士中国业务。 爱施健中国由广州爱施健贸易咨询有限公司及其分公司、山德士（中国）制药有限公司及其分公司组成。 公司广泛的产品组合主要覆盖麻醉、抗血栓、消化、骨质疏松和其他疾病领域，其他包括免疫抑制剂、抗肿瘤药品、生殖系统疾病药物和内分泌系统疾病药物。业务覆盖全国31个省市区的3000多家医院。为了中国患者的切实利益以及实现“2030年健康中国”的目标，爱施健中国将竭尽所能致力于继续在中国上市新的产品。更多信息，请访问： https://www.aspenpharma.cn/。

SAN DIEGO — As researchers explore more potential benefits of GLP-1 medicines, a new retrospective study is suggesting the drug class’ potential to treat venous thromboembolisms, or blood clots in the veins, for individuals with type 2 diabetes. The researchers looked at electronic health records from hundreds of thousands of diabetes patients and compared those who took GLP-1s with another diabetes drug class known as DPP-4 inhibitors. The review found that those who were on GLP-1 drugs had a 20% lower risk of developing the clots after one year. That group also had a 22% lower rate of pulmonary embolisms — clots blocking arteries in the lungs — and an 18% lower rate of deep vein thrombosis. Retrospective studies like this one are useful for finding relationships and suggesting avenues for further study, but the evidence is often considered less persuasive than a randomized, placebo-controlled study. The research was published at the American Society of Hematology annual meeting this weekend. DPP-4 inhibitors were chosen as a control group because they are a commonly used diabetes drug and have no known effect on venous thromboembolisms, lead author Cho Han Chiang told Endpoints News . The research also didn’t separate results by specific GLP-1 drugs. All previously approved drugs were included in the analysis, including newer ones like semaglutide (Novo’s Ozempic and Wegovy) and tirzepatide (Eli Lilly’s Mounjaro and Zepbound), as well as GLP-1s approved in the mid-2000s like exenatide (Lilly’s Byetta). Chiang also included patients who were taking other diabetes drugs like metformin or insulin. The results add to a quickly growing body of evidence that GLP-1 drugs could have broad applications beyond the diabetes and obesity indications that make up the bulk of the market for the drugs. In March, the FDA approved Wegovy to treat cardiovascular disease, and other data have shown potential effects in conditions ranging from liver disease to Parkinson’s and depression. Chiang, a resident at Beth Israel Deaconess Medical Center in Boston, said diabetes and obesity are significant risk factors for venous thromboembolism, one of the reasons he decided to conduct the analysis. There aren’t many medical interventions that can prevent them, he said. “There are some recommendations on the use of low molecular weight heparin and compression stockings,” Chiang said. “But in terms of medical therapy to reduce one of the major risk factors, such as obesity, in contributing to VTE, there’s pretty limited data.” The CDC estimates that there are as many as 900,000 yearly cases of venous thromboembolisms in the US. The next step in Chiang’s research will be to look at conducting a similar analysis specifically for obesity, he said. Other areas where venous thromboembolisms can manifest are some hematological cancers. But whether biopharma companies opt to conduct clinical trials is up to their discretion, he said. “You probably can randomize patients on GLP-1 receptor agonists, and those without, as an add-on therapy to a diabetes regimen” in patients at high risk for developing venous thromboembolisms, Chiang said.